Frank Segrave

Biography

With 33 years of experience in retail, merchandising, distribution, sales, managed care and marketing, Frank founded Silvergate Pharmaceuticals in September 2010. Silvergate is a specialty pharmaceutical company that is focused on filling the unmet needs of pediatric patients. The company’s first drug, Epaned, was approved by the FDA in 2013 to treat pediatric hypertension. In August 2016, the company’s 2nd drug, Qbrelis, was approved for the treatment of pediatric hypertension. Silvergate’s 3rd drug, Xatmep, was approved in April of 2017. Xatmep is approved for the treatment of Acute Lymphoblastic Leukemia and Polyarticular Juvenile Idiopathic Arthritis.

Research Interest

Molecular Biology and Molecular Genetics